

Raquibul Hannan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7794646/publications.pdf>

Version: 2024-02-01

61
papers

1,965
citations

304743

22
h-index

265206

42
g-index

61
all docs

61
docs citations

61
times ranked

3667
citing authors

#	ARTICLE	IF	CITATIONS
1	SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 290-301.	0.8	13
2	Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. <i>European Urology Oncology</i> , 2022, 5, 216-224.	5.4	26
3	Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e9-166.e13.	1.6	17
4	Discordance of patient- and physician-reported toxicities in two prospective trials of stereotactic body radiotherapy (SBRT) for localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 245-245.	1.6	0
5	Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 779182.	2.8	0
6	Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1387-1395.	0.8	14
7	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Eur Urol Focus</i> . 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002 . [Epub ahead of print]. <i>European Urology Focus</i> , 2021, 7, 404-405.	3.1	3
8	Phase II trial of stereotactic ablative radiation (SABR) for oligometastatic kidney cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 311-311.	1.6	5
9	Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021, 27, 3818-3824.	7.0	21
10	Phase II trial of stereotactic ablative radiation (SABR) for oligoprogressive kidney cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4564-4564.	1.6	2
11	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e1-790.e7.	1.6	10
12	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombusâ€”Safety Lead-in Results of a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1135-1142.	0.8	36
13	Hydrogel Spacer Rectal Wall Infiltration Associated With Severe Rectal Injury and Related Complications After Dose Intensified Prostate Cancer Stereotactic Ablative Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2021, 6, 100713.	1.2	14
14	Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1306-1316.	0.8	41
15	A deep learning-based framework for segmenting invisible clinical target volumes with estimated uncertainties for post-operative prostate cancer radiotherapy. <i>Medical Image Analysis</i> , 2021, 72, 102101.	11.6	32
16	Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma. <i>Metabolites</i> , 2021, 11, 608.	2.9	13
17	A Multi-Institutional Phase 2 Trial of High-Dose SABR for Prostate Cancer Using Rectal Spacer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 101-109.	0.8	19
18	PSA-Net: Deep learningâ€”based physician styleâ€”aware segmentation network for postoperative prostate cancer clinical target volumes. <i>Artificial Intelligence in Medicine</i> , 2021, 121, 102195.	6.5	24

#	ARTICLE	IF	CITATIONS
19	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6716-6725.	7.0	12
20	Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 914-916.	0.8	1
21	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. <i>European Urology Oncology</i> , 2020, 3, 728-738.	5.4	61
22	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. , 2020, 8, e001198.		24
23	Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. <i>Seminars in Radiation Oncology</i> , 2020, 30, 129-138.	2.2	27
24	Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. <i>Science Immunology</i> , 2020, 5, .	11.9	39
25	Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 614-614.	1.6	55
26	Safety and outcome of stereotactic body radiation therapy (SBRT) with rectal hydrogel spacer for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 76-76.	1.6	2
27	Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): A phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing for erectile function preservation in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS381-TPS381.	1.6	1
28	A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 647-647.	1.6	0
29	Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.. <i>Journal of Clinical Oncology</i> , 2020, 38, 333-333.	1.6	10
30	Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus â€“ Initial Experience Report and Literature Review. <i>Kidney Cancer</i> , 2019, 3, 71-77.	0.4	7
31	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>European Urology Focus</i> , 2019, 5, 958-969.	3.1	86
32	Addition of Iodinated Contrast to Rectal Hydrogel Spacer to Facilitate MRI-Independent Target Delineation and Treatment Planning for Prostate Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, e528-e533.	2.1	7
33	Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 367-375.	0.8	65
34	PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. , 2019, 7, 144.		53
35	Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e263-e272.	1.9	19
36	Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e273-e280.	1.9	25

#	ARTICLE	IF	CITATIONS
37	Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.. Journal of Clinical Oncology, 2019, 37, 645-645.	1.6	36
38	Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.. Journal of Clinical Oncology, 2019, 37, 599-599.	1.6	0
39	DC-HIL/Gpmb checkpoint blockade as a synergistic combination for stereotactic ablative radiation (SAbR).. Journal of Clinical Oncology, 2019, 37, e14129-e14129.	1.6	0
40	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncolmmunology, 2018, 7, e1440168.	4.6	31
41	Natural history of â€˜secondâ€™ biochemical failure after salvage radiation therapy for prostate cancer: a multiâ€™institution study. BJU International, 2018, 121, 365-372.	2.5	12
42	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancerâ€™specific Mortality: Competition Between Age and Time to Biochemical Failure. European Urology Oncology, 2018, 1, 276-282.	5.4	6
43	PD-L1 on host cells is essential for PD-L1 blockadeâ€™mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 580-588.	8.2	388
44	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. Clinical Genitourinary Cancer, 2018, 16, e1221-e1235.	1.9	14
45	An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. Cancer Discovery, 2018, 8, 1142-1155.	9.4	138
46	Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study.. Journal of Clinical Oncology, 2018, 36, 586-586.	1.6	1
47	Improved survival rates in kidney cancer patients with brain metastases treated with modern multidisciplinary approaches.. Journal of Clinical Oncology, 2018, 36, 601-601.	1.6	0
48	Anatomical patterns of recurrence following biochemical relapse after postâ€™prostatectomy salvage radiation therapy: a multiâ€™institutional study. BJU International, 2017, 120, 351-357.	2.5	10
49	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 91-100.	0.8	67
50	Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunology, Immunotherapy, 2017, 66, 281-298.	4.2	54
51	Stereotactic body radiation therapy for low and intermediate risk prostate cancerâ€™Results from a multi-institutional clinical trial. European Journal of Cancer, 2016, 59, 142-151.	2.8	124
52	Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11300-11305.	7.1	132
53	A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. Annals of Surgical Oncology, 2016, 23, 218-224.	1.5	61
54	Pretreatment biopsy analysis of DAB 2 IP identifies subpopulation of highâ€™risk prostate cancer patients with worse survival following radiation therapy. Cancer Medicine, 2015, 4, 1844-1852.	2.8	7

#	ARTICLE	IF	CITATIONS
55	The combination of radiation therapy and immunotherapy for genitourinary cancer treatment: rationale, current evidence, and prospects. <i>Journal of Radiation Oncology</i> , 2015, 4, 355-363.	0.7	0
56	Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. <i>Cancer Biology and Therapy</i> , 2015, 16, 657-661.	3.4	25
57	Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 699-706.	3.4	32
58	Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. <i>Practical Radiation Oncology</i> , 2014, 4, 409-414.	2.1	7
59	The effects of anticoagulant use in high-risk prostate cancer treated with radiotherapy on overall survival and biochemical control.. <i>Journal of Clinical Oncology</i> , 2014, 32, 146-146.	1.6	0
60	Combined immunotherapy with <i>Listeria monocytogenes</i> -based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2227-2238.	4.2	33
61	Enrichment of "Cribriform" morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer. <i>Modern Pathology</i> , 0, , .	5.5	3